Trials / Recruiting
RecruitingNCT06617000
A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
A Phase 1, Multicenter Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- Sponsor
- SCG Cell Therapy Pte. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I clinical study aimed to assess the safety, tolerability, and efficacy of SCG101 monotherapy for patients with HBV-HCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SCG101 | Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels. |
Timeline
- Start date
- 2022-10-25
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2024-09-27
- Last updated
- 2024-09-27
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06617000. Inclusion in this directory is not an endorsement.